OUR PIPELINE
Expanding what’s possible in cancer treatment
Advancing a new generation of precision therapies through RNA and signaling pathway biology.
EP102 represents the first step in translating RNA epigenetics into patient care.
The ongoing EPICS clinical trial is paving the way for future epigenetic therapies by revealing which cancers respond best to EPICS’s METTL3 inhibitor, EP102, and which tumor indications are most driven by RNA-based epigenetic changes.
The insights gained will sharpen the focus onto responsive tumor types, establish the use of EP102 as a monotherapy and further guide smart combination strategies built on the biology of RNA regulation and its nexus with existing therapies alternatively targeting the DNA damage response.
Beyond METTL3, EPICS is progressing additional RNA epigenetic targets and GPCR-linked (G protein–coupled receptor) discovery programs, including EP601 and EP282 thereby broadening its precision-oncology platform
